AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Anaphylm's FDA A...
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: GlobeNewswire
Promise vs. Reality: The Aquestive Therapeutics Performance Gap Management told investors Anaphylm was "on track" for FDA approval by January 31, 2026. On January 9, 2026, the FDA flagged deficiencies that precluded even labeling discussions. AQST shareholders lost $2.30 per share overnight. NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP highlights the contrast between Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) repeated assurances and what actually happened to investors. Find out if you qualify to recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. AQST shares fell from $6.21 to $3.91 on January 9, 2026, a single-day decline exceeding 37%. The lead plaintiff deadline is May 4, 2026. The Promise Throughout the Class Period (June 16, 2025 through January 8, 2026), the Company projected unwavering confidence in its Anaphylm regulatory path: - June 16, 2025: Management declared the Company was "one ste
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQSTPR Newswire
- AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallStPR Newswire
- Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. InvestorsGlobeNewswire
- AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming DeadlineGlobeNewswire
- AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026GlobeNewswire
AQST
Earnings
- 3/4/26 - Miss
AQST
Sec Filings
- 3/20/26 - Form 8-K
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- AQST's page on the SEC website